Abstract
Calcific aortic stenosis (AS) is the most common form of valvular heart disease requiring intervention in the developed world. Although indolent early in its course, the disease becomes extremely malignant following the development of symptoms with an average survival of only 2–3 years and a high rate of sudden death. Until recently, surgical aortic valve replacement (AVR) had been the only therapy demonstrated to alter the natural history of AS and improve mortality. Standard medical therapy, including balloon aortic valvuloplasty, can lead to a short-term improvement in symptoms, but does not improve survival. The Placement of Aortic Transcatheter Valves (PARTNER) trial compared transcatheter aortic valve replacement (TAVR) with standard therapy in patients with symptomatic, severe AS who were inoperable (cohort B) or high-risk (cohort A) candidates for AVR. In cohort B of the trial, TAVR with the Edwards SAPIEN valve significantly reduced the primary end point of overall mortality at 1 year among patie...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
